74 related articles for article (PubMed ID: 11548302)
1. "What you lookin' at?".
Gormley F
GMHC Treat Issues; 2001 May; 15(5):5-6. PubMed ID: 11548302
[No Abstract] [Full Text] [Related]
2. AIDS researchers emphasize new drug combinations.
Fox JL
Nat Biotechnol; 1997 Mar; 15(3):215. PubMed ID: 9062914
[No Abstract] [Full Text] [Related]
3. HIV's potent cocktail.
Lusky K
Contemp Longterm Care; 1999 Dec; 22(12):59. PubMed ID: 10977335
[No Abstract] [Full Text] [Related]
4. Targeting a deadly scrap of genetic code.
Cowley G
Newsweek; 1996 Dec; 128(23):68-9. PubMed ID: 10162944
[No Abstract] [Full Text] [Related]
5. Lipodystrophy--nukes vs. protease inhibitors.
TreatmentUpdate; 2001 Jul; 13(3):5-6. PubMed ID: 11569989
[No Abstract] [Full Text] [Related]
6. The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.
Wilkins E
J HIV Ther; 2008 Mar; 13(1):9-18. PubMed ID: 18953268
[No Abstract] [Full Text] [Related]
7. Controversies in current treatment guidelines.
Gazzard BG
J HIV Ther; 2008 Mar; 13(1):1-3. PubMed ID: 18953266
[No Abstract] [Full Text] [Related]
8. Patient adherence, not viral load now most important in HIV therapy.
Rep Med Guidel Outcomes Res; 2000 Feb; 11(3):6-7. PubMed ID: 11768406
[No Abstract] [Full Text] [Related]
9. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980
[No Abstract] [Full Text] [Related]
10. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
[TBL] [Abstract][Full Text] [Related]
11. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
12. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
[No Abstract] [Full Text] [Related]
13. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
[TBL] [Abstract][Full Text] [Related]
14. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
[TBL] [Abstract][Full Text] [Related]
15. ABC in the news.
Carter M
IAPAC Mon; 2006 Jun; 12(6):178-9. PubMed ID: 17233104
[No Abstract] [Full Text] [Related]
16. Anti-HIV agents. Saquinavir--switching from Fortovase to Invirase.
TreatmentUpdate; 2004; 16(3):8-9. PubMed ID: 17219608
[No Abstract] [Full Text] [Related]
17. How HIV drugs work 101.
Pietrandoni G
Posit Aware; 2001; 12(5):26-7. PubMed ID: 11688481
[No Abstract] [Full Text] [Related]
18. Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
Gupta Samir K
AIDS Read; 2007 Feb; 17(2):102-3. PubMed ID: 17323509
[No Abstract] [Full Text] [Related]
19. Anti-HIV agents. Atazanavir and saquinavir.
TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
[No Abstract] [Full Text] [Related]
20. Preliminary data on 141W94 reported.
AIDS Patient Care STDS; 1998 Jan; 12(1):65-6. PubMed ID: 11361894
[No Abstract] [Full Text] [Related]
[Next] [New Search]
